Teva, a leading global pharmaceutical company, embarked on a transformation journey two years ago to differentiate itself based on the unique characteristics of our business model and to create a new breed of healthcare company. Building on its strong global footprint, size and scale, Teva is reaffirming a commitment to placing people at the center of our strategy, and enable as many as people possible to live better, healthier days.

Teva is the world’s largest maker of generic medicines, with a global portfolio of more than 1,000 molecules in 35,000 formulations sold in about 100 countries. The company maintains a top three position in 25 markets, and touches approximately 200 million people worldwide each year.

Teva is a world leader in innovative specialty pharmaceuticals, known for its prominent portfolios in Central Nervous System (CNS), including multiple sclerosis, pain, migraine, movement disorders and neurodegenerative diseases, and in respiratory, as well as for its strong commercial presence in oncology and women’s health.